New hope for hard-to-treat myeloma: drug combo shows promise in phase 2 trial
NCT ID NCT05789303
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study is for people with multiple myeloma that has returned or is no longer responding to standard treatments, including CAR T-cell therapy. Researchers are testing a combination of four drugs (belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone) to see if it can shrink tumors or slow the disease. About 83 adults will take part, and the study lasts 6 to 24 months depending on how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.